Michael Hayes


Michael is a serial entrepreneur with over 20 years experience building and leading high-growth organizations. 

He was most recently CEO of FeatureX, an AI startup focused on deep learning computer vision technology. 

Michael started his career as an officer aboard the USS La Jolla (SSN-701), a nuclear-powered fast attack submarine. He is an inventor (US Patent 8732065) and has degrees from Notre Dame, MIT, and The Fletcher School at Tufts University.

Michael was successfully treated for Stage IV throat cancer in 2008.


Regina Barzilay


Regina Barzilay is a professor in the Department of Electrical Engineering and Computer Science and a member of the Computer Science and Artificial Intelligence Laboratory (CSAIL) at the Massachusetts Institute of Technology. Her research interests are in natural language processing and applications of deep learning to chemistry and oncology.

In 2017, she received a MacArthur "genius grant" fellowship, an ACL fellowship and an AAAI fellowship.  She is a recipient of various awards including the NSF Career Award, the MIT Technology Review TR-35 Award, Microsoft Faculty Fellowship and several Best Paper Awards at NAACL and ACL.  She received her Ph.D. in Computer Science from Columbia University, and spent a year as a postdoc at Cornell University. 

Regina for slides and website.jpg
Weinberg_Big thoughful.jpg

Bob Weinberg


Bob is a Founding Member of the Whitehead Institute for Biomedical Research and Professor of Biology at the Massachusetts Institute of Technology. The Weinberg lab is known for its discoveries of the first human oncogene – the Ras oncogene that causes normal cells to form tumors, and the isolation of the first known tumor suppressor gene - the Rb gene.

His lab now primarily focuses on two areas: the interactions between epithelial and mesenchymal cells that produce carcinomas and the processes by which cancer cells invade and metastasize.

Bob is a Member of the U.S. National Academy of Sciences, and his many awards include the National Medal of Science (1997), Wolf Prize in Medicine (2004), Landon-AACR Prize for Cancer Research (2006), Otto Warburg Medal (2007), Breakthrough Prize in Life Sciences (2013), and the Salk Medal (2016).


Jack Szostak


Jack Szostak is biologist, Professor of Genetics at Harvard Medical School, and Alexander Rich Distinguished Investigator at Massachusetts General Hospital, Boston. 

Jack has made significant contributions to the field of genetics. His achievement helped scientists to map the location of genes in mammals and to develop techniques for manipulating genes. His research findings in this area are also instrumental to the Human Genome Project. 

He was awarded the 2009 Nobel Prize for Physiology or Medicine, along with Elizabeth Blackburn and Carol W. Greider, for the discovery of how chromosomes are protected by telomeres.

Gaddy Getz Headshot from Broad.jpg

Gad Getz


Gad Getz directs the Cancer Genome Computational Analysis group at the Broad Institute of MIT and Harvard, where he is an institute member. Under Getz’s leadership, the Cancer Genome Analysis group has established itself as a world leader in the development and application of genomic technologies and next-generation sequencing for analyzing cancer mutations.

In addition to his role at the Broad, Getz is a co-principal investigator in the Genome Data Analysis Center (GDAC) of the NCI/NHGRI TCGA (The Cancer Genome Atlas) project; and a co-leader of the International Cancer Genome Consortium (ICGC) Pan-Cancer Analysis of Whole Genomes (PCAWG) project. In addition, Getz directs the Bioinformatics Program at the Massachusetts General Hospital Cancer Center and Department of Pathology.


Daniel Haber


Dan Haber is the Director of the Cancer Center at Massachusetts General Hospital.

The Haber lab is focused on the area of cancer genetics. Recent research has had important implications for strategies to identify critical genetic lesions in cancers that may serve as an "Achilles heel" and be suitable for molecular targeting. 

Dr. Haber’s group recently established the application of a novel microfluidic technology for quantifying and purifying rare circulating tumor cells (CTCs) in human blood. This new application has potentially profound implications for early diagnosis of cancer and for noninvasive molecular profiling of cancers during the course of therapy.